Jay Strum Email

Chief Scientific Officer . Incyclix Bio

Current Roles

Employees:
7
Revenue:
$542.5k
About
Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.
Incyclix Bio Address
600 Park Offices Dr.
Durham, NC
Incyclix Bio Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.